Vimarsana
Biggest News Aggregation in the World

Belite Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Belite Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Belite Bio Today - Breaking & Trending Today

Belite Bio (NASDAQ:BLTE) Reaches New 1-Year High at $49.25 - Vimarsana News

Belite Bio (NASDAQ:BLTE) Reaches New 1-Year High at $49.25

Belite Bio, Inc (NASDAQ:BLTE – Get Free Report)’s share price hit a new 52-week high during trading on Wednesday . The stock traded as high as $49.25 and last traded at $49.10, with a volume of 46462 shares trading hands. The stock had previously closed at $48.80. Wall Street Analyst Weigh In Several brokerages have […]

Belite Bio (NASDAQ:BLTE) Reaches New 1-Year High at $49.25 - Vimarsana News

Belite Bio (NASDAQ:BLTE) Reaches New 1-Year High at $49.25

Belite Bio, Inc (NASDAQ:BLTE – Get Free Report)’s share price hit a new 52-week high during trading on Wednesday . The stock traded as high as $49.25 and last traded at $49.10, with a volume of 46462 shares trading hands. The stock had previously closed at $48.80. Wall Street Analyst Weigh In Several brokerages have […]

Belite Bio (NASDAQ:BLTE) Stock Rating Reaffirmed by HC Wainwright - Vimarsana News

Belite Bio (NASDAQ:BLTE) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Belite Bio (NASDAQ:BLTE – Free Report) in a research note published on Wednesday, Benzinga reports. The brokerage currently has a $59.00 price target on the stock. HC Wainwright also issued estimates for Belite Bio’s Q2 2024 earnings at ($0.28) EPS, FY2024 earnings at ($1.09) EPS and […]

Belite Bio's (BLTE) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - Vimarsana News

Belite Bio's (BLTE) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Belite Bio (NASDAQ:BLTE – Free Report) in a research report report published on Wednesday, Benzinga reports. Separately, HC Wainwright reaffirmed a buy rating and issued a $59.00 price objective on shares of Belite Bio in a research report on Friday, March 22nd. Seven analysts have rated […]

Source: wkrb13.com
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant - Vimarsana News

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited eye disease...